vs
Freight Technologies, Inc.(FRGT)与Lakeside Holding Ltd(LSH)财务数据对比。点击上方公司名可切换其他公司
Lakeside Holding Ltd的季度营收约是Freight Technologies, Inc.的2.3倍($7.0M vs $3.0M)。Freight Technologies, Inc.净利率更高(21.7% vs -22.6%,领先44.3%)
Freight Technologies, Inc.是一家货运代理企业,代表货主协调、组织货物运输,与海运、空运、陆运、铁路等多领域运输商对接合作,可整合货运资源、协商运输费率、跟进货物运输状态,为单批多式联运货物梳理物流网络,提供专业的货运代理服务。
莱克赛德出版社是位于美国芝加哥的出版品牌,由RR唐纳利公司运营。该社除了出版高品质书籍外,还承印邮购目录、电话号码簿、百科全书与广告宣传品,最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本,以及经典重印丛书《莱克赛德经典》。
FRGT vs LSH — 直观对比
营收规模更大
LSH
是对方的2.3倍
$3.0M
净利率更高
FRGT
高出44.3%
-22.6%
损益表 — Q2 2025 vs Q4 2025
| 指标 | ||
|---|---|---|
| 营收 | $3.0M | $7.0M |
| 净利润 | $649.2K | $-1.6M |
| 毛利率 | — | 27.2% |
| 营业利润率 | -49.2% | -21.3% |
| 净利率 | 21.7% | -22.6% |
| 营收同比 | — | 95.0% |
| 净利润同比 | — | 18.7% |
| 每股收益(稀释后) | $0.02 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
FRGT
LSH
| Q4 25 | — | $7.0M | ||
| Q3 25 | — | $6.1M | ||
| Q2 25 | $3.0M | $6.3M | ||
| Q1 25 | $4.1M | $3.8M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.1M |
净利润
FRGT
LSH
| Q4 25 | — | $-1.6M | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | $649.2K | $-893.1K | ||
| Q1 25 | $-1.6M | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | — | $-1.3M |
毛利率
FRGT
LSH
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 18.2% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 18.8% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 12.8% |
营业利润率
FRGT
LSH
| Q4 25 | — | -21.3% | ||
| Q3 25 | — | -20.8% | ||
| Q2 25 | -49.2% | -8.9% | ||
| Q1 25 | -35.7% | -28.2% | ||
| Q4 24 | — | -55.6% | ||
| Q3 24 | — | -32.5% |
净利率
FRGT
LSH
| Q4 25 | — | -22.6% | ||
| Q3 25 | — | -22.2% | ||
| Q2 25 | 21.7% | -14.2% | ||
| Q1 25 | -39.1% | -28.2% | ||
| Q4 24 | — | -54.1% | ||
| Q3 24 | — | -32.7% |
每股收益(稀释后)
FRGT
LSH
| Q4 25 | — | $-0.08 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | $0.02 | $-0.11 | ||
| Q1 25 | $-0.73 | $-0.14 | ||
| Q4 24 | — | $-0.26 | ||
| Q3 24 | — | $-0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $586.7K | $1.6M |
| 总债务越低越好 | — | $2.4M |
| 股东权益账面价值 | $8.8M | $12.2M |
| 总资产 | $17.1M | $24.3M |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势,按日历期对齐
现金及短期投资
FRGT
LSH
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $4.5M | ||
| Q2 25 | $586.7K | $5.0M | ||
| Q1 25 | $416.5K | $1.5M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $2.7M |
总债务
FRGT
LSH
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $774.2K | ||
| Q4 24 | — | $784.8K | ||
| Q3 24 | — | $589.9K |
股东权益
FRGT
LSH
| Q4 25 | — | $12.2M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | $8.8M | $2.8M | ||
| Q1 25 | $6.2M | $749.8K | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $3.6M |
总资产
FRGT
LSH
| Q4 25 | — | $24.3M | ||
| Q3 25 | — | $18.6M | ||
| Q2 25 | $17.1M | $14.4M | ||
| Q1 25 | $13.4M | $9.9M | ||
| Q4 24 | — | $9.8M | ||
| Q3 24 | — | $10.8M |
负债/权益比
FRGT
LSH
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-1.9M | $-453.5K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | -2.99× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势,按日历期对齐
经营现金流
FRGT
LSH
| Q4 25 | — | $-453.5K | ||
| Q3 25 | — | $-4.0M | ||
| Q2 25 | $-1.9M | $-483.7K | ||
| Q1 25 | $-3.1M | $-238.3K | ||
| Q4 24 | — | $-530.2K | ||
| Q3 24 | — | $-1.4M |
自由现金流
FRGT
LSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-497.4K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-560.5K | ||
| Q3 24 | — | $-1.4M |
自由现金流率
FRGT
LSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -15.6% | ||
| Q3 24 | — | -34.5% |
资本支出强度
FRGT
LSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 0.1% |
现金转化率
FRGT
LSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -2.99× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FRGT
暂无分部数据
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |